Zacks Investment Research downgraded shares of Oxford Immunotec Global PLC (NASDAQ:OXFD) from a hold rating to a sell rating in a research report report published on Wednesday morning.

According to Zacks, “Oxford Immunotec Global PLC is a medical diagnostics company. It develops new tests for various diseases based on its, patented T cell measurement technology. The company’s first product is the T-SPOT(R). Oxford Immunotec Global PLC is headquartered in Abingdon, the United Kingdom. “

A number of other analysts have also recently weighed in on OXFD. BTIG Research restated a buy rating on shares of Oxford Immunotec Global PLC in a report on Thursday, May 4th. ValuEngine upgraded shares of Oxford Immunotec Global PLC from a sell rating to a hold rating in a report on Friday, June 2nd. Piper Jaffray Companies restated a buy rating and set a $26.00 target price on shares of Oxford Immunotec Global PLC in a report on Thursday, August 3rd. Finally, Cowen and Company restated a buy rating and issued a $22.00 price target on shares of Oxford Immunotec Global PLC in a research report on Thursday, August 3rd. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. Oxford Immunotec Global PLC presently has an average rating of Hold and a consensus target price of $20.25.

Oxford Immunotec Global PLC (OXFD) opened at 15.50 on Wednesday. Oxford Immunotec Global PLC has a one year low of $9.49 and a one year high of $19.51. The firm’s 50 day moving average price is $16.55 and its 200-day moving average price is $15.27. The firm’s market cap is $357.68 million.

Oxford Immunotec Global PLC (NASDAQ:OXFD) last issued its earnings results on Tuesday, August 1st. The company reported ($0.32) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.32). The firm had revenue of $26.10 million during the quarter, compared to analysts’ expectations of $25.05 million. Oxford Immunotec Global PLC had a negative net margin of 34.58% and a negative return on equity of 35.76%. The firm’s revenue for the quarter was up 35.9% compared to the same quarter last year. During the same period last year, the firm posted ($0.29) earnings per share. Equities analysts predict that Oxford Immunotec Global PLC will post ($1.63) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Oxford Immunotec Global PLC (OXFD) Downgraded to “Sell” at Zacks Investment Research” was first posted by Watch List News and is owned by of Watch List News. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of US and international copyright & trademark laws. The legal version of this piece can be accessed at https://www.watchlistnews.com/oxford-immunotec-global-plc-oxfd-downgraded-to-sell-at-zacks-investment-research/1533816.html.

In related news, COO Peter Edwardson sold 9,739 shares of the firm’s stock in a transaction on Tuesday, August 15th. The shares were sold at an average price of $16.14, for a total value of $157,187.46. Following the transaction, the chief operating officer now directly owns 92,905 shares in the company, valued at approximately $1,499,486.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Peter Wrighton-Smith sold 32,832 shares of the firm’s stock in a transaction on Wednesday, July 5th. The shares were sold at an average price of $16.58, for a total transaction of $544,354.56. Following the completion of the transaction, the chief executive officer now owns 478,106 shares in the company, valued at $7,926,997.48. The disclosure for this sale can be found here. Insiders have sold a total of 126,195 shares of company stock worth $2,073,682 in the last 90 days. 7.58% of the stock is owned by insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Redmile Group LLC raised its position in Oxford Immunotec Global PLC by 7.5% in the second quarter. Redmile Group LLC now owns 2,155,949 shares of the company’s stock worth $36,263,000 after buying an additional 151,100 shares during the last quarter. AXA raised its position in Oxford Immunotec Global PLC by 52.5% in the first quarter. AXA now owns 917,468 shares of the company’s stock worth $14,212,000 after buying an additional 315,718 shares during the last quarter. Grandeur Peak Global Advisors LLC raised its position in Oxford Immunotec Global PLC by 8.3% in the first quarter. Grandeur Peak Global Advisors LLC now owns 703,378 shares of the company’s stock worth $10,895,000 after buying an additional 53,975 shares during the last quarter. Endurant Capital Management LP raised its position in Oxford Immunotec Global PLC by 3,456.1% in the first quarter. Endurant Capital Management LP now owns 570,971 shares of the company’s stock worth $8,844,000 after buying an additional 554,915 shares during the last quarter. Finally, State Street Corp raised its position in Oxford Immunotec Global PLC by 12.4% in the second quarter. State Street Corp now owns 447,104 shares of the company’s stock worth $7,523,000 after buying an additional 49,274 shares during the last quarter. Institutional investors and hedge funds own 79.13% of the company’s stock.

About Oxford Immunotec Global PLC

Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.

Receive News & Ratings for Oxford Immunotec Global PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.